ClinicalTrials.gg
Enrolling by invitationNCT07942883Updated Nov 17, 2026

BFR and Neuromuscular Training in Knee Osteoarthritis (KOA)

An interventional study of Blood Flow Restricted Low-Load Resistance Training (BFR-LLRT) and Neuromuscular Training (NMT) in Knee Osteoarthritis (KOA), sponsored by University of Lahore. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Lahore · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 135 studies in Osteoarthritis, Knee with a site in Pakistan — 41 open to participants now, 50 under way, none of them phase 3. Osteoarthritis, Knee · Pakistan.

Planned enrollment
Largest of 131
202 · median 44
Started
2026
with 21 others
No phase
130 of 135
41 open now
Primary completion
2027-01
later than 45 of 49 live
Registered
135th of 135
by date
Lead sponsor
8 of 135
University of Lahore

Among the 135 studies in Osteoarthritis, Knee with a site in Pakistan, this one has the largest planned enrollment of the 131 interventional ones that give a count, is one of 22 that started in 2026, is one of 130 with no phase, reaches primary completion later than 45 of the 49 other live ones, and was the 135th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

41 of the 135 studies in Osteoarthritis, Knee with a site in Pakistan are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Osteoarthritis, Knee with a site in Pakistan, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate the effects of blood-flow restricted low-load resistance training combined with neuromuscular training on pain intensity, quadriceps muscle endurance, and quality of life in adults aged 40-75 years with knee osteoarthritis (Kellgren-Lawrence Grade II-III). A total of 202 participants will be allocated into two groups: an experimental group receiving combined BFR and neuromuscular training, and a control group receiving neuromuscular training alone. The intervention will be conducted three times weekly for four weeks. Outcomes will be assessed at baseline, week 2, and week 4 using the Visual Analog Scale (VAS), Repetition-to-Failure Test, and Knee Injury and Osteoarthritis Outcome Score (KOOS). The study aims to determine whether the combined intervention provides greater improvements in pain, muscle endurance, and quality of life.

03

Conditions studied

  • Knee Osteoarthritis (KOA)
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 40-75 years with a clinical and radiographic diagnosis of knee osteoarthritis (Kellgren-Lawrence grade II-III) - to capture moderate, conservatively manageable OA where BFRT is most beneficial. (He et al., 2025)

    • Ability to ambulate independently without assistive devices, allowing safe participation in neuromuscular and resistance exercises. (Petersson et al., 2022)
    • Persistent knee pain ≥ 3 months and functional limitation in daily activities, ensuring chronicity and measurable symptom change. (Wang et al., 2022).
    • (BMI) ≤ 35 kg/m², to reduce load-related confounding and safety risks during BFR. (Machado et al., 2024a)
    • Stable cardiovascular profile and physician clearance for moderate-intensity exercise.

(Jardim et al., 2022a)

  • Willingness to attend all sessions and provide written for participation.

(He et al., 2025)

Exclusion criteria

Exclusion Criteria:

  • Peripheral vascular disease or varicose veins, which may impair venous return during BFR (Fontanet et al., 2025)

    • Neurological or sensory impairment affecting lower-limb function (neuropathy, radiculopathy), which could compromise pain perception and safety. (Pitsillides et al., 2021)
    • Recent orthopedic surgery (\< 6 months) or acute musculoskeletal injury near the knee or hip joint, as healing tissues may not tolerate occlusion. (Petersson et al., 2022)
    • Diabetes mellitus with vascular complications or uncontrolled metabolic disorders, due to heightened ischemic risk (Wang et al., 2022).
    • Active infection, , or renal impairment, identified as systemic to BFRT. (Machado et al., 2024b)
    • Pregnancy, owing to altered vascular physiology and safety considerations. (He et al., 2025)
    • Intolerance to occlusion pressure or exercise pain ≥ 7/10 during familiarization session (Jardim et al., 2022b)
    • Concurrent participation in other physiotherapy or pharmacologic interventions for knee OA, to avoid confounding effects. (Grantham et al., 2021)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
202 participants (estimated)

Study arms

  • Active comparator
    Neuromuscular Training Alone

    Participants will receive supervised neuromuscular training three times per week on alternate days (Monday, Wednesday, and Friday) for four consecutive weeks. Each session will last approximately 40 minutes and include a 5-minute warm-up, balance and proprioception exercises (single-leg stance), strength and motor control exercises (mini-squats, step-downs, and terminal knee extensions using resistance bands), dynamic stability and functional activities (side-stepping, forward lunges, weight-shifting, and sit-to-stand exercises), followed by cool-down stretching. Exercises will be performed under the supervision of a qualified physiotherapist.

    Behavioral: Blood Flow Restricted Low-Load Resistance Training (BFR-LLRT) · Behavioral: Neuromuscular Training (NMT)

  • Experimental
    Blood Flow Restricted Low-Load Resistance Training Combined with Neuromuscular Training

    Participants will receive blood-flow restricted low-load resistance training combined with neuromuscular training three times per week on alternate days for four consecutive weeks. A non-pneumatic elastic strap will be applied to the proximal thigh to partially restrict venous return. Participants will perform seated knee extensions and seated leg curls at 30% of one-repetition maximum (1RM), using one set of 30 repetitions followed by three sets of 15 repetitions, with 30-second rest intervals. Following the blood-flow restriction component, participants will perform the same neuromuscular training protocol as the comparator group, including balance, proprioception, strength, coordination, and functional stability exercises. All sessions will be supervised by a qualified physiotherapist with appropriate safety monitoring.

    Behavioral: Blood Flow Restricted Low-Load Resistance Training (BFR-LLRT) · Behavioral: Neuromuscular Training (NMT)

Interventions

  • BehavioralBlood Flow Restricted Low-Load Resistance Training (BFR-LLRT)

    Blood-flow restricted low-load resistance training will be performed using a non-pneumatic elastic strap applied to the proximal thigh to partially restrict venous return. The strap will be tightened to a perceived pressure of 7/10, corresponding to approximately 60-80% arterial occlusion pressure. Participants will perform seated knee extensions and seated leg curls at 30% of one-repetition maximum (1RM), consisting of one set of 30 repetitions followed by three sets of 15 repetitions, with 30-second rest intervals. The cuff will be released between exercises for reperfusion. Training will be supervised by a qualified physiotherapist three times per week for four weeks.

  • BehavioralNeuromuscular Training (NMT)

    Neuromuscular training will consist of structured exercises designed to improve knee joint proprioception, balance, coordination, and functional stability. The protocol will include single-leg stance on firm and unstable surfaces, mini-squats, step-downs, terminal knee extensions using resistance bands, side-stepping, forward lunges, weight-shifting drills, and sit-to-stand exercises. Sessions will include warm-up and cool-down activities and will be conducted under the supervision of a qualified physiotherapist three times per week for four consecutive weeks, with approximately 40 minutes per session.

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity Measured by Visual Analog Scale (VAS)

    Time frame: Baseline (Week 0), Week 2, and Week 4 after intervention.

07

Study locations

1 site
  • UIPT, UOL, Lahore
    Lahore, Punjab Province 54000, Pakistan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 1,111 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 2 months is below that.

Counting every sponsor, half of 1,251 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942883
Responsible party
Shumaila Anwar (Dr. Shumaila Anwar, University of Lahore) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion